0001599298-24-000070.txt : 20240415
0001599298-24-000070.hdr.sgml : 20240415
20240415092146
ACCESSION NUMBER: 0001599298-24-000070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240411
FILED AS OF DATE: 20240415
DATE AS OF CHANGE: 20240415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ronaghi Mostafa
CENTRAL INDEX KEY: 0001441876
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 24843294
MAIL ADDRESS:
STREET 1: 9885 TOWNE CENTRE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-460-8308
MAIL ADDRESS:
STREET 1: 2882 SAND HILL ROAD
STREET 2: SUITE 106
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wk-form4_1713187295.xml
FORM 4
X0508
4
2024-04-11
0
0001599298
Summit Therapeutics Inc.
SMMT
0001441876
Ronaghi Mostafa
C/O SUMMIT THERAPEUTICS INC.
601 BRICKELL KEY DRIVE, SUITE 1000
MIAMI
FL
33131
1
0
0
0
0
Stock Option (right to buy)
4.03
2024-04-11
4
A
0
200000
A
2034-04-11
Common Stock
200000
200000
D
Stock Option (right to buy)
4.03
2024-04-11
4
A
0
25315
A
2034-04-11
Common Stock
25315
225315
D
The option was granted on April 11, 2024. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on April 11, 2025, subject to the director remaining as a non-salaried director on each such vesting date.
Not applicable.
The option was granted on April 11, 2024 and represents a pro rata amount of the annual 35,000 option board grant based approximately on the number of days the reporting person is anticipated to serve as a director in 2024. The shares underlying the option are scheduled to vest in full on December 31, 2024, subject to the director remaining as a non-salaried director on such vesting date.
/s/ Bhaskar Anand, as Attorney-in-Fact for Mostafa Ronaghi
2024-04-15